Acadia Pharmaceuticals Files 8-K on Financials

Ticker: ACAD · Form: 8-K · Filed: 2025-02-26T00:00:00.000Z

Sentiment: neutral

Topics: financial-reporting, 8-k

Related Tickers: ACAD

TL;DR

ACADIA dropped an 8-K on Feb 26th detailing financial results. Check it out.

AI Summary

Acadia Pharmaceuticals Inc. filed an 8-K on February 26, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits related to the company's performance.

Why It Matters

This filing provides investors with crucial updates on Acadia Pharmaceuticals' financial health and operational performance, impacting investment decisions.

Risk Assessment

Risk Level: low — This is a routine financial reporting filing and does not indicate any immediate or significant risks.

Key Players & Entities

FAQ

What specific financial information is being reported in this 8-K?

The 8-K filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.

When was this 8-K report filed?

The report was filed on February 26, 2025.

What is the principal business address of Acadia Pharmaceuticals Inc.?

The principal executive offices are located at 12830 El Camino Real, Suite 400, San Diego, California, 92130.

What is the Commission File Number for Acadia Pharmaceuticals Inc.?

The Commission File Number is 000-50768.

Under which section of the Securities Exchange Act is this report filed?

This Current Report is filed Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

From the Filing

0000950170-25-027759.txt : 20250226 0000950170-25-027759.hdr.sgml : 20250226 20250226161522 ACCESSION NUMBER: 0000950170-25-027759 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20250226 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250226 DATE AS OF CHANGE: 20250226 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001070494 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 061376651 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-50768 FILM NUMBER: 25670242 BUSINESS ADDRESS: STREET 1: 12830 EL CAMINO REAL STREET 2: SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 858-558-2871 MAIL ADDRESS: STREET 1: 12830 EL CAMINO REAL STREET 2: SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 8-K 1 acad-20250226.htm 8-K 8-K false 0001070494 0001070494 2025-02-26 2025-02-26   UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025     Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter)     Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)           12830 El Camino Real, Suite 400   San Diego , California   92130 (Address of Principal Executive Offices)   (Zip Code)   Registrant’s Telephone Number, Including Area Code: (858) 558-2871   N/A (Former Name or Former Address, if Changed Since Last Report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.0001 per share   ACAD   The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐   Item 2.02 Results of Operations and Financial Condition. On February 26, 2025, Acadia Pharmaceuticals Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2024. A copy of this press release is furnished herewith as Exhibit 99.1. Pursuant to the rules and regulations of the Securities and Exchange Commission, such exhibit and the information set forth therein and in this Item 2.02 have been furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under that section nor shall they be

View on Read The Filing